Thrombolysis in stroke: Inappropriate consideration of the 'window period' as the time available;Trombólisis en el ictus: Consideración inapropiada del 'período de ventana' como tiempo disponible

Revista de Neurologia

Volumn 40, Issue 5, 2005, Pages 274-278

  Maestre Moreno, José F ^a   Fernandez Perez M D ^a   Arnaiz Urrutia C ^a   Minguez A ^a   Navarrete Navarro, P ^a   Martinez Bosch J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Delay; Health care organisation; Intravenous thrombolysis; Ischaemic stroke; r TPA; Therapeutic attitude

Indexed keywords

ALTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATIONAL STUDY; DEMOGRAPHY; DISEASE SEVERITY; EMERGENCY CARE; FEMALE; HEALTH CARE; HOSPITAL CARE; HUMAN; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD; THERAPY DELAY; TREATMENT DURATION; TREATMENT INDICATION; BRAIN ISCHEMIA; FIBRINOLYTIC THERAPY; MIDDLE AGED; TIME;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; MALE; MIDDLE AGED; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 30944455722     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4005.2004356     Document Type: Article

References (10)

1. The ATLANTIS, ECASS and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 769-74.
2. Registro SITS-MOST. Safe Implementation of Thrombolysis in Stroke-Monitoring Study. URL: http://www.acutestroke.org. Fecha última consulta: 24.06.2004.
3. Barber PA, Denchuk AM, Zhang J, Buchan AM for the ASPECTS Study Group. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet 2000; 355: 1670-4.
4. Broderick JP. Logistics in acute stroke management. Drugs 1997; 54 (Suppl 3): 116-7.
5. Álvarez-Sabin J, Molina C, Abilieira S, Montaner J, García F, Alijotas J. 'Código Ictus' y tiempos de latencia en el tratamiento de reperfusión durante la fase aguda del ictus isquémico. Med Clin (Barc) 1999; 113: 481-3.
6. Álvarez-Sabin J, Molina CA, Abilieira S, Montaner J, García-Alfranca F, Jiménez-Fabrega X, et al. Impacto de la activación del Código Ictus en la eficacia del tratamiento trombolítico. Med Clin (Barc) 2003; 120: 47-51.
7. Kwan J, Hand P, Sandercock P. Improving the efficiency of delivery of thrombolysis for acute stroke: a systematic review. QJM 2004; 97: 273-9.
8. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke. The Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JAMA 2000; 283: 1145-50.
9. Chapman KM, Woolfenden AR, Graeb D, Johnston DCC, Beckman J, Schulzer M, et al. Intravenous tissue plasminogen activator for acute ischemic stroke. A Canadian hospital's experience. Stroke 2000; 31: 2920-24.
10. Szoeke CEI, Parsons MW, Butcher KS, Baird TA, Mitchell PJ, Fox SE, et al. Acute stroke thrombolysis with intravenous plasminogen activator in an Australian tertiary hospital. Medical Journal of Australia 2003; 178: 324-8.